Researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and the University of Massachusetts Medical School have developed a strategy to treat two of the most common inherited blood diseases—sickle cell disease and beta thalassemia—applying CRISPR-Cas9 gene editing to patients’ own blood stem cells. Described this week in Nature Medicine and in a January report in the journal Blood, their approach overcomes prior technical challenges, editing blood stem cells more efficiently than in the past.
From https://medicalxpress.com/news/2019-03-optimize-gene-scd-beta-thalassemia.html
from https://karlfletcher.blogspot.com/2019/03/researchers-optimize-gene-editing-for.html
from
https://karlfletcher1.tumblr.com/post/183787792148
From https://davidrawlins1.blogspot.com/2019/03/researchers-optimize-gene-editing-for.html
from
https://davidrawlins1.wordpress.com/2019/03/29/researchers-optimize-gene-editing-for-scd-and-beta-thalassemia/
No comments:
Post a Comment